Fertility preservation in BRCA mutation carriers-efficacy and safety issues: a review

Xiaofu Zhang, Jingxin Niu, Tuanjie Che, Yibei Zhu, Hongtao Zhang, Jing Qu, Xiaofu Zhang, Jingxin Niu, Tuanjie Che, Yibei Zhu, Hongtao Zhang, Jing Qu

Abstract

BRCA mutation carriers face various situations that influence their fertility potential. There is still a lack of guideline or expert consensus on Fertility Preservation (FP) in BRCA mutation carriers and the necessity and safety of FP in BRCA mutation carriers is still in dispute. This review aims to focus on the population of BRCA mutation carriers by analyzing the existing FP strategies, comprehensively comparing the pros and cons of each strategy and its applicability.FP is a suggestion for BRCA mutation carriers with birth planning. Different FP strategies have different characteristics. Considering the particularity of BRCA mutation carriers, multiple factors need to be carefully considered. This review focuses on the applicability of each FP method for carriers under various circumstances. Available FP strategies including oocyte cryopreservation, ovarian tissue cryopreservation, preimplantation genetic diagnosis, and egg/embryo donation are analyzed by comparing existing methods comprehensively. In the attempt to provide an up-to-date decision-making guidance. Conditions taking into consideration were the carrier's age, the risk of breast and ovarian metastasis, plans for oncotherapy, FP outcome, time available for FP intervention and accessibility.Overall, FP is necessary and safe for BRCA mutation carriers. Among all available FP methods, oocyte cryopreservation is the most reliable procedure; ovarian tissue cryopreservation is the only way for preserving both fertility and endocrine function, recommended for pre-pubertal carriers and when time is limited for oocyte stimulation. A clear framework provides frontline clinical practitioners a new thought and eventually benefit thousands of BRCA mutation carriers.

Keywords: BRCA mutation; Fertility preservation; In vitro fertilization; Infertility.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
BRCA mutation and it’s negative impact on reproductive potential
Fig. 2
Fig. 2
Flow chart of OTC procedure
Fig. 3
Fig. 3
The procedure of PGD
Fig. 4
Fig. 4
Individualized strategies of FP for BRCA mutation carriers
Fig. 5
Fig. 5
Suggestions for fertility preservation (FP) candidates

References

    1. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science (New York, NY) 1990;250(4988):1684–1689. doi: 10.1126/science.2270482.
    1. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (New York, NY) 1994;265(5181):2088–2090. doi: 10.1126/science.8091231.
    1. Dasika GK, Lin S-CJ, Zhao S, Sung P, Tomkinson A, Lee EYHP. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene. 1999;18(55):7883–7899. doi: 10.1038/sj.onc.1203283.
    1. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995;10(8):1673–1675.
    1. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet. 1992;2(2):128–131. doi: 10.1038/ng1092-128.
    1. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10(26):3001–3007. doi: 10.1093/hmg/10.26.3001.
    1. Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27(8):1449–1455. doi: 10.1093/annonc/mdw142.
    1. Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, et al. Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer. JAMA. 2007;297(23):2587–2595. doi: 10.1001/jama.297.23.2587.
    1. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4(10):814–819. doi: 10.1038/nrc1457.
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersRisks of Breast, Ovarian, and Contralateral Breast Cancer Among BRCA Mutation CarriersRisks of Breast, Ovarian, and Contralateral Breast Cancer Among BRCA Mutation Carriers. JAMA. 2017;317(23):2402–2416. doi: 10.1001/jama.2017.7112.
    1. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2007;40:17. doi: 10.1038/ng.2007.53.
    1. Ahmed M, Lalloo F, Evans DG. Update on genetic predisposition to breast cancer. Expert Rev Anticancer Ther. 2009;9(8):1103–1113. doi: 10.1586/era.09.38.
    1. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average Risks of Breast and Ovarian Cancer Associated with <em>BRCA1</em> or <em>BRCA2</em> Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. Am J Hum Genet. 2003;72(5):1117–1130. doi: 10.1086/375033.
    1. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014;111(39):14205–14210. doi: 10.1073/pnas.1415979111.
    1. Han X, Jemal A. Recent Patterns in Genetic Testing for Breast and Ovarian Cancer Risk in the U.S. Am J Prev Med. 2017;53(4):504–507. doi: 10.1016/j.amepre.2017.04.014.
    1. Vergote I, Banerjee S, Gerdes A-M, van Asperen C, Marth C, Vaz F, et al. Current perspectives on recommendations for <em>BRCA</em> genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127–134. doi: 10.1016/j.ejca.2016.10.006.
    1. Anglian Breast Cancer Study G Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer. 2000;83(10):1301–1308. doi: 10.1054/bjoc.2000.1407.
    1. Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694–1706. doi: 10.1093/jnci/djj465.
    1. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700–710. doi: 10.1086/318787.
    1. Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol Oncol. 2003;89(3):494–498. doi: 10.1016/S0090-8258(03)00152-5.
    1. Derks-Smeets IAP, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, et al. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. J Assist Reprod Genet. 2017;34(11):1475–1482. doi: 10.1007/s10815-017-1014-3.
    1. Lambertini M, Goldrat O, Toss A, Azim HA, Jr, Peccatori FA, Ignatiadis M, et al. Fertility and pregnancy issues in <em>BRCA</em>-mutated breast cancer patients. Cancer Treat Rev. 2017;59:61–70. doi: 10.1016/j.ctrv.2017.07.001.
    1. Rzepka-Górska I, Tarnowski B, Chudecka-Głaz A, Górski B, Zielińska D, Tołoczko-Grabarek A. Premature Menopause in Patients with BRCA1 Gene Mutation. Breast Cancer Res Treat. 2006;100(1):59–63. doi: 10.1007/s10549-006-9220-1.
    1. Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a <em>BRCA1</em> or <em>BRCA2</em> mutation. Fertil Steril. 2013;99(6):1724–1728. doi: 10.1016/j.fertnstert.2013.01.109.
    1. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240–244. doi: 10.1200/JCO.2009.24.2057.
    1. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21. doi: 10.1126/scitranslmed.3004925.
    1. Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA, Jr, Desir J, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2017;29(1):237–243. doi: 10.1093/annonc/mdx639.
    1. Giordano S, Garrett-Mayer E, Mittal N, Smith K, Shulman L, Passaglia C, et al. Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. J Adolesc Young Adult Oncol. 2016;5(4):337–343. doi: 10.1089/jayao.2016.0009.
    1. Phillips K-A, for the Kathleen Cuningham Consortium for Research into Familial Breast C. Collins IM, for the Kathleen Cuningham Consortium for Research into Familial Breast C. Milne RL, for the Kathleen Cuningham Consortium for Research into Familial Breast C et al. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126–1132. doi: 10.1093/humrep/dew044.
    1. Wang ET, Pisarska MD, Bresee C, Ida Chen Y-D, Lester J, Afshar Y, et al. <em>BRCA1</em> germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723–1728. doi: 10.1016/j.fertnstert.2014.08.014.
    1. Son K-A, Lee D-Y, Choi D. Association of BRCA Mutations and Anti-müllerian Hormone Level in Young Breast Cancer Patients. Front Endocrinol. 2019;10:235. doi: 10.3389/fendo.2019.00235.
    1. Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701. doi: 10.1093/humupd/dmu020.
    1. de la Noval BD. Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women. Arch Gynecol Obstet. 2016;294(5):1099–1103. doi: 10.1007/s00404-016-4187-6.
    1. Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2013;31(31):3914–3919. doi: 10.1200/JCO.2012.47.7893.
    1. Lambertini M, Goldrat O, Toss A, Azim HA, Peccatori FA, Ignatiadis M, et al. Fertility and pregnancy issues in BRCA-mutated breast cancer patients. Cancer Treat Rev. 2017;59:61–70. doi: 10.1016/j.ctrv.2017.07.001.
    1. Shapira M, Raanani H, Meirow D. IVF for fertility preservation in breast cancer patients--efficacy and safety issues. J Assist Reprod Genet. 2015;32(8):1171–1178. doi: 10.1007/s10815-015-0519-x.
    1. Bu R, Siraj AK, Al-Obaisi KAS, Beg S, Al Hazmi M, Ajarim D, et al. Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. Int J Cancer. 2016;139(5):1091–1097. doi: 10.1002/ijc.30143.
    1. M. CostaConxi LazaroLidia FeliubadalóBegoña GrañaIgnacio BlancoMiguel de la HoyaTrinidad CaldésPhilippe MailletGaelle Benais-PontBruno PardoYael LaitmanEitan FriedmanEladio A. VelascoMercedes DuránMaria-Dolores MiramarAna Rodriguez ValleMaría-Teresa CalvoAna VegaAna BlancoOrland DiezSara Gutiérrez-EnríquezJudith BalmañaTeresa Ramon y CajalCarmen AlonsoMontserrat BaigetWilliam FoulkesMarc TischkowitzRachel KyleNelly SabbaghianPatricia Ashton-ProllaIngrid P. EwaldThangarajan RajkumarLuisa Mota-VieiraGiuseppe GianniniAlberto GulinoMaria I. AchatzDirce M. CarraroBrigitte Bressac de PailleretsAudrey RemenierasCindy BensonSilvia CasadeiMary-Claire KingErik TeugelsManuel R. Teixeira APSPPJSRGAvdH-MGTAKCS-JBUCRLYPNR International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat. 2011;127(3):671–679. doi: 10.1007/s10549-010-1036-3.
    1. Peixoto A, Salgueiro N, Santos C, Varzim G, Rocha P, Soares MJ, et al. BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Familial Cancer. 2006;5(4):379–387. doi: 10.1007/s10689-006-0009-5.
    1. Kwong A, Ng EKO, Wong CLP, Law FBF, Au T, Wong HN, et al. Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. PLoS One. 2012;7(9):e43994. doi: 10.1371/journal.pone.0043994.
    1. Kwong A, Wong LP, Wong HN, Law FBF, Ng EKO, Tang YH, et al. A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat. 2009;117(3):683–686. doi: 10.1007/s10549-009-0385-2.
    1. Cao W-M, Gao Y, Yang H-J, Xie S-N, Ding X-W, Pan Z-W, et al. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer. BMC Cancer. 2016;16(1):64. doi: 10.1186/s12885-016-2107-6.
    1. Li W-F, Hu Z, Rao N-Y, Song C-G, Zhang B, Cao M-Z, et al. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat. 2008;110(1):99–109. doi: 10.1007/s10549-007-9708-3.
    1. Fang M, Zhu L, Li H, Li X, Wu Y, Wu K, et al. Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population. Oncol Lett. 2017;15. 10.3892/ol.2017.7717.
    1. Shi Tingyan, Wang Pan, Xie Caixia, Yin Sheng, Shi Di, Wei Congchong, Tang Wenbin, Jiang Rong, Cheng Xi, Wei Qingyi, Wang Qing, Zang Rongyu. BRCA1andBRCA2mutations in ovarian cancer patients from China: ethnic-related mutations inBRCA1associated with an increased risk of ovarian cancer. International Journal of Cancer. 2017;140(9):2051–2059. doi: 10.1002/ijc.30633.
    1. Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, et al. The Relative Contribution of Point Mutations and Genomic Rearrangements in <em>BRCA1</em> and <em>BRCA2</em> in High-Risk Breast Cancer Families. Cancer Res. 2008;68(17):7006–7014. doi: 10.1158/0008-5472.Can-08-0599.
    1. Pujadelauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284. doi: 10.1016/S1470-2045(17)30469-2.
    1. Hansen AR, Bedard PL. Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. Breast Cancer Res. 2013;15(5):1–10. doi: 10.1186/bcr3558.
    1. Laurent C, Sophie K, Antoine R, Angélina L, Jean-Jacques B, Olivia B, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014;22(11):1305–1313. doi: 10.1038/ejhg.2014.16.
    1. Ellison G, Wallace A, Kohlmann A, Patton S. A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories. Br J Cancer. 2017;117(5):710–716. doi: 10.1038/bjc.2017.223.
    1. Drohan B, Roche CA, Cusack JC, Hughes KS. Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers. Ann Surg Oncol. 2012;19(6):1732–1737. doi: 10.1245/s10434-012-2257-y.
    1. Hampel H, Sweet K, Westman JA, Offit K, Eng C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet. 2004;41(2):81. doi: 10.1136/jmg.2003.010918.
    1. Bellcross C, Hermstad A, Tallo C, Stanislaw C. Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST™) Genet Med. 2019;21(1):181–184. doi: 10.1038/s41436-018-0020-x.
    1. Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med. 2009;11:783. doi: 10.1097/GIM.0b013e3181b9b04a.
    1. Ovarian tissue cryopreservation: a committee opinion. Fertil Steril. 2014;101(5):1237–43. 10.1016/j.fertnstert.2014.02.052.
    1. Arslan M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril. 2005;84(3):555–569. doi: 10.1016/j.fertnstert.2005.02.053.
    1. Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril. 2013;99(6):1496–1502. doi: 10.1016/j.fertnstert.2013.03.020.
    1. Vuković P, Kasum M, Raguž J, Lonjak N, Bilić Knežević S, Orešković I, et al. Fertility preservation in young women with early-stage breast cancer. Acta Clin Croat. 2019;58(1):147–156. doi: 10.20471/acc.2019.58.01.19.
    1. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–1680. doi: 10.1016/j.fertnstert.2013.07.1992.
    1. Nakasuji T, Kawai K, Ishikawa T, Teraoka K, Takeuchi S, Miyagawa T, et al. Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer. Reprod Med Biol. 2019;18(2):167–172. doi: 10.1002/rmb2.12263.
    1. Larman MG, Minasi MG, Rienzi L, Gardner DK. Maintenance of the meiotic spindle during vitrification in human and mouse oocytes. Reprod BioMed Online. 2007;15(6):692–700. doi: 10.1016/S1472-6483(10)60537-8.
    1. Luciano AM, Chigioni S, Lodde V, Franciosi F, Luvoni GC, Modina SC. Effect of different cryopreservation protocols on cytoskeleton and gap junction mediated communication integrity in feline germinal vesicle stage oocytes. Cryobiology. 2009;59(1):90–95. doi: 10.1016/j.cryobiol.2009.05.002.
    1. Gomes C, Merlini M, Konheim J, Serafini P, Motta EL, Baracat EC, et al. Oocyte meiotic-stage-specific differences in spindle depolymerization in response to temperature changes monitored with polarized field microscopy and immunocytochemistry. Fertil Steril. 2012;97(3):714–719. doi: 10.1016/j.fertnstert.2011.12.018.
    1. Silber S. Ovarian tissue cryopreservation and transplantation: scientific implications. J Assist Reprod Genet. 2016;33(12):1595–1603. doi: 10.1007/s10815-016-0814-1.
    1. Donnez J, Dolmans M-M. Fertility Preservation in Women. N Engl J Med. 2017;377(17):1657–1665. doi: 10.1056/NEJMra1614676.
    1. Donnez J, Dolmans M-M. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet. 2015;32(8):1167–1170. doi: 10.1007/s10815-015-0544-9.
    1. Hoekman EJ, Louwe LA, Rooijers M, van der Westerlaken LAJ, Klijn NF, Pilgram GSK et al. Ovarian tissue cryopreservation: low usage rates and high life birth rate after transplantation. Acta Obstetricia et Gynecologica Scandinavica.0(ja). 10.1111/aogs.13735.
    1. Rodriguez-Wallberg KA, Tanbo T, Tinkanen H, Thurin-Kjellberg A, Nedstrand E, Kitlinski ML, et al. Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries - compilation of 20 years of multicenter experience. Acta Obstet Gynecol Scand. 2016;95(9):1015–1026. doi: 10.1111/aogs.12934.
    1. Imbert R, Moffa F, Tsepelidis S, Simon P, Delbaere A, Devreker F, et al. Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Hum Reprod. 2014;29(9):1931–1940. doi: 10.1093/humrep/deu158.
    1. Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod. 2015;30(3):608–615. doi: 10.1093/humrep/deu353.
    1. Shi Q, Xie Y, Wang Y, Li S. Vitrification versus slow freezing for human ovarian tissue cryopreservation: a systematic review and meta-anlaysis. Sci Rep. 2017;7(1):8538. 10.1038/s41598-017-09005-7.
    1. Abir R, Ben-Aharon I, Garor R, Yaniv I, Ash S, Stemmer SM, et al. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy. Hum Reprod. 2016;31(4):750–762. doi: 10.1093/humrep/dew007.
    1. Kristensen SG, Giorgione V, Humaidan P, Alsbjerg B, Bjørn AB, Ernst E, et al. Fertility preservation and refreezing of transplanted ovarian tissue-a potential new way of managing patients with low risk of malignant cell recurrence. Fertil Steril. 2017;107(5):1206–1213. doi: 10.1016/j.fertnstert.2017.03.017.
    1. Jensen AK, Kristensen SG, Macklon KT, Jeppesen JV, Fedder J, Ernst E, et al. Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod. 2015;30(12):2838–2845. doi: 10.1093/humrep/dev230.
    1. Takae S, Suzuki N. Current state and future possibilities of ovarian tissue transplantation. Reprod Med Biol. 2019;18(3):217–224. doi: 10.1002/rmb2.12268.
    1. Bastings L, Beerendonk CCM, Westphal JR, Massuger LFAG, Kaal SEJ, van Leeuwen FE, et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update. 2013;19(5):483–506. doi: 10.1093/humupd/dmt020.
    1. Pacheco F, Oktay K. Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis. Reprod Sci. 2017;24(8):1111–1120. doi: 10.1177/1933719117702251.
    1. Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, Rasmussen PE, et al. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril. 2011;95(6):2158–2161. doi: 10.1016/j.fertnstert.2010.12.019.
    1. Vermeulen M, Giudice MG, Del Vento F, Wyns C. Role of stem cells in fertility preservation: current insights. Stem Cells Cloning. 2019;12(undefined):27–48.
    1. Akahori T, Woods DC, Tilly JL. Female Fertility Preservation through Stem Cell-based Ovarian Tissue Reconstitution In Vitro and Ovarian Regeneration In Vivo. Clin Med insights Reprod Health. 2019;13(undefined):1179558119848007.
    1. Arav A, Patrizio P. Techniques of Cryopreservation for Ovarian Tissue and Whole Ovary. Clin Med insights Reprod Health. 2019;13(undefined):1179558119884945.
    1. Sheshpari S, Shahnazi M, Mobarak H, Ahmadian S, Bedate AM, Nariman-Saleh-Fam Z, et al. Ovarian function and reproductive outcome after ovarian tissue transplantation: a systematic review. J Transl Med. 2019;17(1):396. doi: 10.1186/s12967-019-02149-2.
    1. Sagi M, Weinberg N, Eilat A, Aizenman E, Werner M, Girsh E, et al. Preimplantation genetic diagnosis for BRCA1/2—a novel clinical experience. Prenat Diagn. 2009;29(5):508–513. doi: 10.1002/pd.2232.
    1. Paluch-Shimon S, Meirow D, Hyman J. Reproductive Issues in BRCA Mutation Carriers. In: Biglia N, Peccatori FA, editors. Breast Cancer, Fertility Preservation and Reproduction. Cham: Springer International Publishing; 2015. pp. 83–102.
    1. De Rycke M, Goossens V, Kokkali G, Meijer-Hoogeveen M, Coonen E, Moutou C. ESHRE PGD Consortium data collection XIV–XV: cycles from January 2011 to December 2012 with pregnancy follow-up to October 2013†. Hum Reprod. 2017;32(10):1974–1994. doi: 10.1093/humrep/dex265.
    1. Wang Q, Chow JFC, Yeung WSB, Lau EYL, Lee VCY, Ng EHY, et al. Preimplantation genetic diagnosis using combined strategies on a breast cancer patient with a novel genomic deletion in BRCA2. J Assist Reprod Genet. 2014;31(12):1719–1726. doi: 10.1007/s10815-014-0355-4.
    1. Harton GL, De Rycke M, Fiorentino F, Moutou C, SenGupta S, Traeger-Synodinos J, et al. ESHRE PGD consortium best practice guidelines for amplification-based PGD†. Hum Reprod. 2010;26(1):33–40. doi: 10.1093/humrep/deq231.
    1. Richards L. The importance of early referral to fertility preservation. Nat Rev Clin Oncol. 2010;8:4. doi: 10.1038/nrclinonc.2010.200.
    1. Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of Early Referral to Fertility Preservation in Young Women With Breast Cancer. J Clin Oncol. 2010;28(31):4683–4686. doi: 10.1200/JCO.2010.30.5748.
    1. Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018;8(undefined):CD012464.
    1. ACOG Practice Bulletin No. 103 Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009;113(4):957–966. doi: 10.1097/AOG.0b013e3181a106d4.
    1. Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod. 2017;33(2):181–187. doi: 10.1093/humrep/dex356.
    1. Kasum M, von Wolff M, Franulić D, Čehić E, Klepac-Pulanić T, Orešković S, et al. Fertility preservation options in breast cancer patients. Gynecol Endocrinol. 2015;31(11):846–851. doi: 10.3109/09513590.2015.1081684.
    1. Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study. Cancer Causes Control. 2008;19(10):1111–1119. doi: 10.1007/s10552-008-9175-0.
    1. Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. J Clin Oncol. 2015;33(22):2424–2429. doi: 10.1200/JCO.2014.59.3723.
    1. Kim J-Y, Moon H-G, Kang Y-J, Han W, Noh W-C, Jung Y, et al. The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are BRCA Mutation Carrier. J Breast Cancer. 2017;20(3):279–285. doi: 10.4048/jbc.2017.20.3.279.
    1. Blakely LJ, Buzdar AU, Lozada JA, Shullaih SA, Hoy E, Smith TL, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004;100(3):465–469. doi: 10.1002/cncr.11929.
    1. Dabrosin C. An overview of pregnancy and fertility issues in breast cancer patients. Ann Med. 2015;47(8):673–678. doi: 10.3109/07853890.2015.1096953.
    1. Trefoux-Bourdet A, Reynaud-Bougnoux A, Body G, Ouldamer L. Grossesse après cancer du sein : revue de la littérature. Presse Med. 2019;48(4):376–383. doi: 10.1016/j.lpm.2019.01.011.
    1. Córdoba O, Bellet M, Vidal X, Cortés J, Llurba E, Rubio IT, et al. Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. Breast. 2012;21(3):272–275. doi: 10.1016/j.breast.2011.10.001.
    1. Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42. doi: 10.1186/bcr3138.
    1. Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019;30(10):1601–1612. doi: 10.1093/annonc/mdz228.
    1. Stopenski S, Aslam A, Zhang X, Cardonick E. After Chemotherapy Treatment for Maternal Cancer During Pregnancy, Is Breastfeeding Possible? Breastfeed Med. 2017;12(undefined):91–97. doi: 10.1089/bfm.2016.0166.
    1. Leal SC, Stuart SR, Carvalho Hde A. Breast irradiation and lactation: a review. Expert Rev Anticancer Ther. 2013;13(2):159–164. doi: 10.1586/era.12.178.
    1. Shah NM, Scott DM, Kandagatla P, Moravek MB, Cobain EF, Burness ML, et al. Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer. Ann Surg Oncol. 2019;26(5):1214–1224. doi: 10.1245/s10434-019-07156-7.
    1. Marion D, Jos CD, Inge D-S, Edith C. Ron vG, Jannie vE-A et al. PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers. Eur J Hum Genet Ejhg. 2013;21(12):1361–1368. doi: 10.1038/ejhg.2013.50.
    1. Derks-Smeets IAP, Gietel-Habets JJG, Tibben A, Tjan-Heijnen VCG, Meijer-Hoogeveen M, Geraedts JPM, et al. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer. Hum Reprod. 2014;29(5):1103–1112. doi: 10.1093/humrep/deu034.
    1. Hoskins LM, Allison WL. A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18-25. J Genet Couns. 2013;22(1):27–38. doi: 10.1007/s10897-012-9521-y.
    1. Gietel-Habets JJG, de Die-Smulders CEM, Derks-Smeets IAP, Tibben A, Tjan-Heijnen VCG, van Golde R, et al. Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners. Hum Reprod. 2017;32(3):588–597. doi: 10.1093/humrep/dew352.
    1. Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, et al. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;145(1):122–129. doi: 10.1016/j.ygyno.2017.02.008.
    1. Goetsch AL, Wicklund C, Clayman ML, Woodruff TK. Reproductive Endocrinologists’ Utilization of Genetic Counselors for Oncofertility and Preimplantation Genetic Diagnosis (PGD) Treatment of BRCA1/2 Mutation Carriers. J Genet Couns. 2016;25(3):561–571. doi: 10.1007/s10897-015-9908-7.
    1. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994–2001. doi: 10.1200/JCO.2018.78.1914.
    1. Azim AA, Maria CF, Lostritto K, Kutluk O. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab. 2007;92(6):2197–2200. doi: 10.1210/jc.2007-0247.
    1. Domingo J, Garciavelasco JA. Oocyte cryopreservation for fertility preservation in women with cancer. Cur Opi Endocrinol Diab Obes. 2016;23(6):465. doi: 10.1097/MED.0000000000000295.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅